New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export MRK’s income statement to Excel — free account
Merck & Co., Inc.
MRKHealthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −12.1%
- Free cash flow
- −19.3%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
134.50
1.76
+1.33%
Follow MRK
Alert me
Merck & Co., Inc. 10-Q filed Nov 5, 2025
What changed
Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 5, 2025: no comparison — the Item was not found